{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:10:33Z","timestamp":1761059433367,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1164,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.bbmt.2011.10.042","type":"journal-article","created":{"date-parts":[[2011,11,7]],"date-time":"2011-11-07T19:01:22Z","timestamp":1320692482000},"page":"318-323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Dasatinib as Salvage Therapy for Steroid Refractory and Imatinib Resistant or Intolerant Sclerotic Chronic Graft-versus-Host Disease"],"prefix":"10.1016","volume":"18","author":[{"given":"Isabel","family":"S\u00e1nchez-Ortega","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Octavio","family":"Servitje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Arnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Ort\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Peralta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Manresa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael F.","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2011.10.042_bib1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199907013410103","article-title":"Long-term survival and late deaths after allogeneic bone marrow transplantation: Late Effects Working Committee of the International Bone Marrow Transplant Registry","volume":"341","author":"Socie","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2011.10.042_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbmt.2010.05.011","article-title":"Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease","volume":"17","author":"Wolff","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.042_bib3","first-page":"258","article-title":"Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome","volume":"91","author":"Skert","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2011.10.042_bib4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2011.10.042_bib5","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials","volume":"108","author":"Roy","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.042_bib6","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis","volume":"354","author":"Baroni","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2011.10.042_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2007-01-071043","article-title":"Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease","volume":"110","author":"Svegliati","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.042_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.22314","article-title":"Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis","volume":"56","author":"Distler","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"Suppl 5","key":"10.1016\/j.bbmt.2011.10.042_bib9","doi-asserted-by":"crossref","first-page":"v10","DOI":"10.1093\/rheumatology\/ken276","article-title":"Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis","volume":"47","author":"Distler","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.bbmt.2011.10.042_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/art.24186","article-title":"Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis","volume":"60","author":"Akhmetshina","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bbmt.2011.10.042_bib11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2008.252","article-title":"Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD","volume":"42","author":"Magro","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.042_bib12","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/archderm.144.9.1106","article-title":"Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease","volume":"144","author":"Moreno-Romero","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bbmt.2011.10.042_bib13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood-2009-02-204750","article-title":"Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease","volume":"114","author":"Magro","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.042_bib14","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","article-title":"Imatinib for refractory chronic graft-versus-host disease with fibrotic features","volume":"114","author":"Olivieri","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.042_bib15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/107327480901600205","article-title":"Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors","volume":"16","author":"McFarland","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.bbmt.2011.10.042_bib16","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/art.23436","article-title":"Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis","volume":"58","author":"Skhirtladze","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bbmt.2011.10.042_bib17","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1096\/fj.07-105627","article-title":"Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis","volume":"22","author":"Akhmetshina","year":"2008","journal-title":"FASEB J"},{"key":"10.1016\/j.bbmt.2011.10.042_bib18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.042_bib19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.042_bib20","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood-2005-09-3907","article-title":"Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD","volume":"107","author":"Couriel","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.042_bib21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/bmt.2009.20","article-title":"Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?","volume":"44","author":"Breccia","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.042_bib22","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/bmt.2009.368","article-title":"Development of severe sclerotic chronic GVHD during treatment with dasatinib","volume":"45","author":"Pulanic","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.042_bib23","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myleoid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111004678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111004678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:42:52Z","timestamp":1761057772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879111004678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S1083879111004678"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.10.042","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dasatinib as Salvage Therapy for Steroid Refractory and Imatinib Resistant or Intolerant Sclerotic Chronic Graft-versus-Host Disease","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.10.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}